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ABSTRACT: Some tumor-associated antigens (TAAs) are expressed on
inflammatory cells. We previously detected carcinoembryonic antigen
(CEA; CD66) in the rheumatoid (RA) synovium. The production of
CEA, CA19-9, CA125, and CA15.3, may be increased in patients with
RA, scleroderma, lupus, and Sjögren’s syndrome (SS). Some of these
TAAs contain sialylated carbohydrate motifs and they are involved in
tumor-associated cell adhesion and metastasis. We assessed levels of
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TAAs in the sera of RA patients and healthy subjects. Serum TAA levels
were correlated with disease markers including serum rheumatoid factor
(RF), C-reactive protein (CRP), and anti-CCP antibody levels, DAS28,
age disease duration. TAAs including CEA, CA15-3, CA72-4, CA125, and
CA19-9, and neuron-specific enolase (NSE) were assessed by immunoas-
say in the sera of 75 patients with RA and 50 age- and sex-matched healthy
controls. Normal upper limits for these TAAs were 3.4 g/L, 25 kU/L,
6.9 kU/L, 35 kU/L, 34 kU/L, and 16.3 g/L, respectively. There were sig-
nificantly more RA patients showing abnormally high levels of CA125
(10.8% versus 7.1%), CA19-9 (8.1% versus 0%), and CA15-3 (17.6%
versus 14.3%) in comparison to controls (P < 0.05). The mean absolute
serum levels of CA125 (23.9 ± 1.8 versus 16.8 ± 2.2 kU/L) and CA19-9
(14.2 ± 1.2 versus 10.5 ± 1.6 kU/L) were also significantly higher in
RA compared to controls (P < 0.05). Among RA patients, serum CEA
showed significant correlation with RF (r = 0.270; P < 0.05). None of the
assessed TAAs showed any correlation with CRP, anti-CCP, DAS28, age
or disease duration. The concentration of some TAAs may be elevated in
the sera of patients with established RA in comparison to healthy sub-
jects. CEA, CA19-9, CA125, and CA15-3 contain carbohydrate motifs
and thus they may be involved in synovitis-associated adhesive events.
Furthermore, some TAAs, such as CEA, may also correlate with prog-
nostic factors, such as serum RF levels.
KEYWORDS: rheumatoid arthritis; tumor antigens; anti-CCP antibody;
rheumatoid factor; carcinoembryonic antigen
INTRODUCTION
Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disease
that affects approximately 0.5–1% of the population. Chronic synovitis in RA
may eventually lead to joint destruction. The etiology of the disease is still
unknown, however, both genetic and environmental factors play an important
role in the onset of RA. The follow-up of patients including the determination
of disease activity and prognostic markers is very important for the introduction
of effective therapeutic strategies and for disease outcome.1
Several laboratory markers including autoantibodies have been associated
with disease activity and/or prognosis of RA.1 IgM rheumatoid factor (RF) is a
good prognostic marker, but does not follow disease activity. It has rather low
specificity for RA.2 C-reactive protein (CRP) is a convenient and sensitive
marker of inflammatory activity in clinical practice. The control of inflam-
mation by antirheumatic therapy usually leads to suppression of serum CRP
levels.3 Anticyclic citrullinated peptide (CCP) has been identified as a diag-
nostic and prognostic marker of RA. The presence of anti-CCP antibodies is
highly specific and sensitive for RA. Anti-CCP is a prognostic marker, as it
may predict persistent, erosive, more aggressive synovitis.4,5 Some investi-
gators found a correlation between anti-CCP and RF positivity.6,7 However,
others found no such relationship.8
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TABLE 1. Tumor-associated antigens
CEA 180 kDa Colon, pancreas, lung
sLe-x: adhesion
CA15-3 300–450 kDa Breast
MUC1: adhesion
CA19-9 sLe-a: adhesion Colon, pancreas, biliary
CA125 200 kDa Ovary
MUC16: adhesion
CA72-4 400 kDa gp GI, ovary, lung
NSE 87 kDa enolase Neuroblastoma, lung
There have been reports showing that tumor-associated antigens (TAAs)
may, apart from cancer cells, become expressed on the surface of inflammatory
cells. These TAAs may play a role in the perpetuation of inflammation. Some
may even serve as cell adhesion receptors. These TAAs may shed from the cell
surface and can be readily detected in the sera of cancer patients.9–12
Perhaps the most well-known TAAs are the CD66 antigens, or the car-
cinoembryonic antigen (CEA) family. The five members of this TAA fam-
ily, CD66a-e, belong to the immunoglobulin superfamily of cell adhesion
molecules (CAM).9,13,14 These antigens contain carbohydrate motifs including
Lewis-x (Le-x) and sialyl-Lewis-x (sLe-x) and they are present on colorectal
and gastric carcinoma cells.15,16 However, besides being present on tumor cells,
CD66 antigens were described for the first time to be present on inflammatory
leukocytes as well.9,15,17–19 The CD66 molecules mediate the adhesion of tu-
mor cells and neutrophils to activated endothelium during metastasis formation
and inflammation, respectively. CD66 antigens bind to E-selectin.14,15,20 We
and others detected CEA-related antigens (CD66b and CD66c) on neutrophils
and monocyte/macrophages.9,15,19,21 In addition, we and others detected an in-
creased expression of CD66 in the RA synovial tissue in comparison to normal
synovia.9,19
Apart from the CEA family, other TAAs may also be associated with in-
flammatory diseases. Among these TAAs, CA15-3 is expressed on breast
carcinoma, CA19-9 on pancreatic carcinoma, CA125 on ovarian carcinoma,
CA72-4 on gastric and mucinous ovarian carcinoma, and neuron-specific eno-
lase (NSE) on small-cell lung carcinoma and neuroblastoma (TABLE 1). Recent
scattered studies revealed that some of these TAAs may also be present in pa-
tients with other autoimmune diseases.22–26 Abundant CA19-9 was detected in
the sera of some RA,22 systemic sclerosis (SSc),23 primary Sjögren’s syndrome
(SS),10,26 mixed connective tissue disease (MCTD),10 and myositis patients.10
Increased CA125 production has been associated with pleural effusion in SSc
and systemic lupus erythematosus (SLE).23,25 Furthermore, serum CA15-3
levels were elevated in a subset of SSc with severe lung involvement.24 How-
ever, little information is available on the association of TAAs described above
and RA.
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Not only members of the CD66 family, but also other TAAs may act as CAM.
CA19-9, CA125, and CA15-3 contain carbohydrate determinants and they are
involved in the adhesive properties of tumor cells and possibly inflammatory
leukocytes. Sialyl-Lewis-a (sLe-a), a blood group antigen, is the immune deter-
minant of CA19-9. sLe-x and sLE-a are ligands of E-selectin.27 CA125 is also
known as MUC16, a giant mucin-like glycoprotein, which mediates ovarian
cancer cell adhesion.11 CA15-3 is another large transmembrane glycoprotein
also termed MUC1. MUC1 is involved in metastasis in breast cancer.12 Fur-
thermore, CA15-3/MUC1 mediates transendothelial tumor cell migration by
ligating endothelial intercellular adhesion molecule-1 (ICAM-1).28 The role
of carbohydrate antigen CAMs, including Lewis antigens, in RA-associated
adhesive events has been elucidated.29,30
In this study, we assessed serum TAA levels in RA patients in comparison
to healthy controls. In addition, TAA production in RA patients was correlated




Altogether 75 RA patients were included in the study. The patient population
contained 62 women and 13 men, their mean age was 50.1 ± 13.8 years (range:
38–75 years). The mean disease duration was 10.9 ± 8.6 years (range: 1–44
years). Fifty age- (mean age: 54.5 ± 9.3 years; range: 43–79 years) and sex-
matched (41 women and 9 men) healthy blood donors served as controls. None
of the RA patients or controls ever had any malignancies. Serum samples were
obtained from all patients and controls. All sera were assayed for TAAs, while
RA patient sera were also submitted for the determination of RF, CRP, and anti-
CCP concentrations. Clinical activity of RA was determined by the calculation
of Disease Activity Score (DAS28). Institutional Ethical Committee approval
was obtained for this study.
Determination of Serum Tumor Antigen Concentrations
TAAs including CEA, CA19-9, CA15-3, CA125, CA72-4, and NSE were
determined by electrochemiluminescence immunoassays using the Modular
E170 automated analyzer (Roche, Basel, Switzerland), according to the manu-
facturer’s instructions. The normal upper limit for these TAAs, determined by
the manufacturer, was as follows: CEA 3.4 g/L, CA19-9 34 kU/L, CA15-3
25 kU/L, CA125 35 kU/L, CA72-4 6.9 kU/L, and NSE 16.3 g/L. All RA and
normal sera were assayed for these TAAs, and the percentage of “positive”
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patients (values above the upper limit), as well as the absolute values of serum
concentrations was compared. In addition, absolute TAA concentrations in the
sera of RA patients were correlated with the corresponding RF, CRP, and anti-
CCP levels (see below). In correlation studies, patients with values above or
below the upper or lower cutoff were excluded.
Determination of RF, CRP, and Anti-CCP Antibody
Serum IgM RF and CRP levels were assessed by quantitative nephelometry
(Cobas Mira Plus; Roche, Basel, Switzerland), using RF and CRP reagents
(Dialab, Budapest, Hungary). RF values >50 U/mL and CRP values ≥5 mg/L
were regarded as positive. Anti-CCP autoantibodies were detected in serum
samples using Immunoscan-RA CCP2 ELISA test (Eurodiagnostica, Arnhem,
the Netherlands). The assay was performed according to the manufacturer’s
instructions. A serum concentration >25 U/mL was considered positive.
Statistical Analysis
The descriptive data of normally distributed variables are expressed as the
mean ± SD. Statistical analysis was carried out by paired two-tailed t-test.
Correlations between variables were determined using the Pearson correlation
coefficient. P-values < 0.05 were considered significant.
RESULTS
Serum CA19-9, CA125, and CA15-3 Levels Are More Frequently Elevated
in RA
When TAA concentrations were determined in the sera of RA patients and
controls, significantly more RA patients exhibited abnormally high levels (val-
ues above the upper normal limit) of CA19-9 (8.1% of patients versus 0% of
controls), CA125 (10.8% versus 7.1%), and CA15-3 (17.6% versus 14.3%)
(P < 0.05). There were no statistically significant differences between RA pa-
tients and controls regarding the serum levels of CEA (22.2% versus 21.4%),
CA72-4 (2.7% versus 2.1%), and NSE (23.0% versus 24.6%) (FIG. 1).
The Absolute Concentrations of CA19-9 and CA125 Are Higher in RA
The mean serum levels of CA19-9 (14.2 ± 1.2 versus 10.5 ± 1.6 kU/L) and
CA125 (23.9 ± 1.8 versus 16.8 ± 2.2 kU/L) were also significantly higher in
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FIGURE 1. Percentage of RA patients and controls with elevated TAA serum levels
(above upper normal limit). CA19-9, CA125, and CD15-3 concentrations were elevated
in significantly more RA patients than healthy subjects. Asterisks indicate statistically
significant differences (P < 0.05).
RA compared to controls (P < 0.05). There were no significant differences
between RA patients and controls in serum CEA (1.8 ± 0.9 versus 2.6 ± 1.6
g/L), CA15-3 (18.6 ± 3.3 versus 19.2 ± 5.3 kU/L), CA72-4 (2.5 ± 1.6 versus
1.5 ± 1.4 kU/L), and NSE (13.7 ± 4.5 versus 16.3 ± 7.8 g/L) (FIG. 2).
Correlation between TAA Levels and Other Markers in RA
When serum concentrations of two distinct TAAs were correlated in the RA
patients, CA125 showed significant correlation with CA15-3 (r = 0.377, P <
0.05) (FIG. 3).
Regarding laboratory markers of disease activity and/or prognosis, only
serum CEA levels showed significant correlation with RF (r = 0.270; P <
0.05) (FIG. 4). In addition, RF levels also correlated with anti-CCP (r = 0.275,
P < 0.05) (FIG. 5) and CRP production (r = 0.473, P < 0.05) (FIG. 6), but
not with any TAAs (data not shown). None of the assessed TAAs showed any
correlation with CRP, anti-CCP, DAS28, age, or disease duration (data not
shown).
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FIGURE 2. Mean TAA serum levels in RA patients and controls. The mean concen-
trations of CA19-9 and CA125 were higher in RA patients compared to controls. Asterisks
indicate statistically significant differences (P < 0.05).
DISCUSSION
Apart from tumor cells, TAAs may be expressed by inflammatory leukocytes
and, in soluble form, TAAs may be readily detected in the sera of cancer
patients, as well as that of patients with various autoimmune inflammatory
diseases.10,19,21–26 In this study, we assessed serum levels of CEA, CA19-9,
CA125, CA15-3, CA72-4, and NSE in 75 RA patients and 50 control subjects.
All of these TAAs were readily detectable in most RA and control sera.
When investigating and comparing the percentage of RA patients and con-
trol subjects with elevated serum TAA levels (serum concentrations above the
upper normal limit), significantly more RA patients were “TAA positive” for
CA19-9 (8% versus 0%), CA125 (11% versus 7%), and CA15-3 (18% versus
14%) than healthy subjects. In addition, when mean serum levels were ana-
lyzed, the serum concentrations of CA19-9 (14 versus 10.5 kU/L) and CA125
(24 versus 17 kU/L) were also elevated in RA compared to controls. “TAA pos-
itivity” for or serum levels of CEA, CA72-4, and NSE were not different in the
patients and controls. There is relatively little information available regarding
soluble TAA production in RA. CA19-9 has been detected in the sera of RA,
as well as SLE, SSc, SS, MCTD, and myositis patients.10,22,26 However, the
increased production of CA125 or CA15-3 in RA has not yet been confirmed.
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FIGURE 3. Significant correlation between serum CA125 and CA15-3 levels in RA
patients (P < 0.05).
FIGURE 4. Significant correlation between serum RF and CEA concentrations in RA
patients (P < 0.05).
Increased CA125 production has been associated with pleural effusion in SSc
and SLE.23,25 Serum levels of CA15-3 were elevated in SSc associated with
severe pulmonary involvement.24 We and others have previously detected the
expression of CEA on synovial leukocytes in RA.9,19,21 However, in this study,
the increased production of soluble CEA in RA was not confirmed. In sum-
mary, CA19-9, CA125, and possibly CA15-3 production may be increased in
RA compared to healthy subjects.
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FIGURE 5. Significant correlation between serum RF and anti-CCP antibody levels
in RA patients (P < 0.05).
FIGURE 6. Significant correlation between serum RF and CRP levels in RA patients
(P < 0.05).
When performing correlation analysis between any two TAAs, only serum
CA125 and CA15-3 levels could be significantly correlated (P < 0.05). These
data underscore the possible association of these two TAAs with RA. We have
not found any other studies where serum levels of various soluble TAAs were
correlated with each other in RA.
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In order to search for possible disease activity and/or prognostic markers
among the TAAs, serum TAA levels were correlated with serum concentra-
tions of IgM RF, CRP, and anti-CCP antibodies, as well as with the clinical
activity score DAS28. Only CEA levels showed significant correlation with
RF production (P < 0.05). Although we could not detect elevated soluble CEA
production in RA patients compared to healthy controls, soluble CEA is readily
detectable in most RA sera, and previous studies showed synovial expression
of cellular CEA.9,19,21 In addition, in the early report by Unger et al.,21 ele-
vated plasma CEA levels were detected in seropositive, but not seronegative
RA patients, which again underscores a possible association between CEA and
RF production.
The exact pathogenic role of TAAs in RA remains to be elucidated. Among
TAAs investigated in this study, CEA, CA19-9, CA125, and CA15-3, but
not CA72-3 and NSE, contain carbohydrate motifs and exert adhesive prop-
erties during tumor metastasis formation. The CEA family (CD66a-CD66e
antigens) belongs to the immunoglobulin superfamily of CAMs.13 The CD66
antigens contain the oligosaccharides LeX and sLeX16; it has been postulated
that neutrophils may use CD66 to bind to E-selectin expressed by activated
endothelium.15,19 Although in the present study we were unable to detect in-
creased production of soluble CEA in RA, previous studies confirmed that
there is abundant expression of CD66 and E-selectin in the RA synovium.9,31
Here we also demonstrated significant positive correlation between CEA and
RF production in RA. Thus, CEA may be involved in adhesive interactions
underlying synovial inflammation.
In this study, we found increased production of CA19-9, CA125, and CA15-
3, but not that of CA72-4 and NSE in RA. Interestingly, CA19-9, CA125,
and CA15-3 have been associated with intercellular adhesion, but CA72-
4 and NSE have not. These three TAAs, as well as CEA, contain carbo-
hydrate motifs and have been implicated in adhesive events underlying tu-
mor metastasis.11,12,27,28,32,33 The immune determinant of CA19-9 is another
Lewis antigen, sLe-a. sLe-a is also a ligand for the CAM E-selectin.27 A
correlation between CA19-9 and ICAM-1 production in inflammatory liver
disease suggests that these two CAMs may be simultaneously overexpressed
during inflammatory processes.27 CA125, a giant mucin-like glycoprotein,
also known as MUC16, mediates cell adhesion to mesothelin, a glycosyl-
phosphatidylinositol-linked cell-surface molecule. Mesothelin is expressed in
many tumor cells. The interaction of CA125/MUC16 and mesothelin is in-
volved in the adhesion of ovarian cancer cells during metastasis formation.11
CA125 also binds to galectin-1, a cell-surface lectin implicated in cell adhesion,
proliferation, and apoptosis.32 Finally, CA15-3 is also known as MUC1. CA15-
3/MUC1 is the most widely used serum marker in breast cancer. This is a large
transmembrane glycoprotein mediating cancer cell adhesion during metas-
tasis.12 It has been shown recently, that CA15-3/MUC1 ligates endothelial
ICAM-1 and thus mediates transendothelial migration of tumor cells.28 This
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TAA has also been implicated in T cell migration and lymphocyte–endothelial
adhesion in inflammation.33 The role of Lewis antigens including Le-y in RA
has been confirmed.29,30 We have not found any reports regarding possible
adhesive properties of CA72-4 or NSE. Thus, in this study, only TAAs acting
as CAMs exerted abundant production in RA.
As secondary results, in this study we also confirmed that RF production is
significantly correlated with serum anti-CCP and CRP levels (P < 0.05). RF is
a prognostic marker, which has been correlated with unfavorable disease out-
come. However, RF is not a disease activity marker. CRP is an activity marker,
while anti-CCP levels have been associated with both disease activity and pro-
gression.2–5 There is controversy regarding possible correlations between RF
and anti-CCP production, as some investigators found positive correlation,6,7
while others could not confirm this.8
In conclusion, some TAAs including CA19-9, CA125, and CA15-3, car-
bohydrate antigens with adhesive properties, exert increased production in
RA. Thus, these TAAs may be involved in intercellular adhesion underlying
synovial inflammation. Furthermore, the production of some TAAs, such as
CEA, may correlate with serum RF concentrations suggesting that soluble
TAA measurements may have prognostic relevance in RA.
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